The European Union Reported the Absence of an Application for Registration of the "Sputnik V" vaccine
The publication says that at the moment EMA has not gotten an implementation for approval of the "Sputnik V" vaccine, which was designed by the National Research Center for Epidemiology and Microbiology in Russia.
EMA also said that they had provided an opportunity to apply, and the Russian Direct Investment Fund said that the implementation had already been submitted.
On February 2, the medical journal The Lancet informed the results of the third phase of clinical trials of the Russian vaccine shows 91.6 percent effectiveness against coronavirus. 19,866 people took part in testing the vaccine.